MRNA

$MRNA

Moderna, Inc.

mRNA therapeutics and vaccines pioneer known for COVID-19 vaccine.

Healthcare
$205.90
-9.37 (-4.35%)
Day Range$205.31 - $219.85
Prev Close$215.27

MRNA key facts as of November 14, 2026

Latest AI research report
MRNA Stock: Costs, Cancer Pipeline and Risks (as of November 14, 2026)
StockAlpha report sentiment
Bearish (as of November 14, 2026)
Analyst consensus
Hold (1 Strong Buy, 3 Buy, 16 Hold, 2 Sell, 2 Strong Sell) (as of November 1, 2026)
Analyst price target
$143.67 mean (range $25.00 to $305.00) (as of November 17, 2026)
Sector
Healthcare
Analyst Rating
Hold
4 Buy / 16 Hold / 4 Sell
Price Target
$143.67
-30.2% downside
Subscribers
1
Tracking this ticker
Latest Report

Analysis from Nov 13, 2026

BEARISH

MRNA Stock: Costs, Cancer Pipeline and Risks

Moderna reported a Q3 EPS beat and is advancing a planned cancer-therapy filing, but rising cost concerns and uncertain revenue visibility weighed on the shares heading into the weekend. The analyst consensus is Hold, with the supplied mean target 34% below Friday’s closing price.

Nov 14, 2026

MRNA FAQ

What is StockAlpha's latest view on MRNA?

StockAlpha's latest AI research report on Moderna, Inc. (MRNA), "MRNA Stock: Costs, Cancer Pipeline and Risks", was published on November 14, 2026 and rates the overall sentiment as bearish. Moderna reported a Q3 EPS beat and is advancing a planned cancer-therapy filing, but rising cost concerns and uncertain revenue visibility weighed on the shares heading into the weekend. The analyst consensus is Hold, with the supplied mean target 34% below Friday’s closing price.

When was the MRNA research last updated?

The most recent MRNA report was published on November 14, 2026.

What do analysts expect for MRNA?

As of November 1, 2026, the analyst consensus on MRNA is Hold (1 Strong Buy, 3 Buy, 16 Hold, 2 Sell, 2 Strong Sell). As of November 17, 2026, the analyst price target is $143.67 mean (range $25.00 to $305.00).

Is this MRNA research investment advice?

No. StockAlpha.ai research is AI-generated analysis for informational purposes only and is not investment advice. Analyst figures are third-party data. Do your own research before making investment decisions.

Keep exploring